Antibe Therapeutics Inc
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSA… Read more
Antibe Therapeutics Inc (ATBPF) - Total Assets
Latest total assets as of December 2023: $56.36 Million USD
Based on the latest financial reports, Antibe Therapeutics Inc (ATBPF) holds total assets worth $56.36 Million USD as of December 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Antibe Therapeutics Inc - Total Assets Trend (2012–2023)
This chart illustrates how Antibe Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Antibe Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (March 2023)
Antibe Therapeutics Inc's total assets of $56.36 Million consist of 58.9% current assets and 41.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.6% |
| Accounts Receivable | $1.61 Million | 2.3% |
| Inventory | $40.00K | 0.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $26.35 Million | 37.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2023)
This chart illustrates how Antibe Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Antibe Therapeutics Inc's current assets represent 58.9% of total assets in 2023, a decrease from 67.2% in 2012.
- Cash Position: Cash and equivalents constituted 9.6% of total assets in 2023, down from 54.7% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 37.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 37.4% of total assets.
Antibe Therapeutics Inc Competitors by Total Assets
Key competitors of Antibe Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Antibe Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Antibe Therapeutics Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Antibe Therapeutics Inc is currently not profitable relative to its asset base.
Antibe Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.06 | 15.71 | 3.63 |
| Quick Ratio | 10.05 | 15.38 | 2.67 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $25.30 Million | $ 41.69 Million | $ 7.66 Million |
Antibe Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Antibe Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.60 |
| Latest Market Cap to Assets Ratio | 0.16 |
| Asset Growth Rate (YoY) | -20.9% |
| Total Assets | $70.56 Million |
| Market Capitalization | $10.98 Million USD |
Valuation Analysis
Below Book Valuation: The market values Antibe Therapeutics Inc's assets below their book value (0.16 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Antibe Therapeutics Inc's assets decreased by 20.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Antibe Therapeutics Inc (2012–2023)
The table below shows the annual total assets of Antibe Therapeutics Inc from 2012 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-03-31 | $70.56 Million | -20.86% |
| 2022-03-31 | $89.16 Million | +9.07% |
| 2021-03-31 | $81.74 Million | +490.70% |
| 2020-03-31 | $13.84 Million | -6.62% |
| 2019-03-31 | $14.82 Million | +18.64% |
| 2018-03-31 | $12.49 Million | +16.46% |
| 2017-03-31 | $10.73 Million | +10.12% |
| 2016-03-31 | $9.74 Million | +1133.99% |
| 2015-03-31 | $789.32K | -81.86% |
| 2014-03-31 | $4.35 Million | +489.61% |
| 2013-03-31 | $738.02K | +331.98% |
| 2012-03-31 | $170.85K | -- |